Similar values for CNS ORR have been reported for crizotinib, ceritinib, and lorlatinib.47 In comparison, CNS ORRs for less BBB-penetrant targeted therapies for patients with NSCLC and IMD have been reported at lower values for ceritinib (45.0%; 95% CI, 23.1%-68.5%; 9 of 20 patients), an ALK inhibitor,48 and for erlotinib hydrochloride (44.3%; 95% CI, 35.8%-53.1%; n = 238), an EGFR inhibitor.49 It is possible that these discrepancies are because of differences in sample size. This evidence concerns the gene ALK and non-small cell lung carcinoma.